Last reviewed · How we verify
alogliptin + pioglitazone
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | alogliptin + pioglitazone |
|---|---|
| Also known as | Nesina, Actos |
| Sponsor | Kun-Ho Yoon |
| Drug class | DPP-4 inhibitor + thiazolidinedione |
| Target | DPP-4 and PPAR-γ |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This combination targets type 2 diabetes through two complementary pathways. Alogliptin prevents the breakdown of incretin hormones, enhancing glucose-dependent insulin secretion and reducing glucagon. Pioglitazone acts as an insulin sensitizer by activating PPAR-γ in adipose tissue and muscle, reducing hepatic glucose production and improving peripheral glucose uptake.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Fluid retention / edema
- Headache
- Upper respiratory tract infection
Key clinical trials
- The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD (PHASE4)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
- A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322 (PHASE4)
- A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alogliptin + pioglitazone CI brief — competitive landscape report
- alogliptin + pioglitazone updates RSS · CI watch RSS
- Kun-Ho Yoon portfolio CI